This study investigates ketamine's effectiveness in simultaneously addressing major depressive episodes and alcohol dependence. By administering a single dose of ketamine, researchers aim to observe a rapid and sustained reduction in depressive symptoms, assessed by the Hamilton Depression Rating Scale, in subjects with these co-occurring conditions. The study also emphasizes ketamine's safety and minimal adverse effects in this specific patient group. Conducted as a double-blind, randomized, placebo-controlled crossover trial, it seeks to unveil potential advancements in treating these often co-occurring and challenging conditions, possibly reshaping clinical approaches for patients struggling with both depression and alcohol dependence.